Drug Profile


Alternative Names: ATN-103; PF-05230896; PF5230896; TS-152

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ablynx
  • Developer Ablynx; Eddingpharm; Pfizer; Taisho Pharmaceutical
  • Class Antirheumatics; Monoclonal antibodies; Proteins
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Discontinued Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis

Most Recent Events

  • 30 Jul 2015 Phase-II clinical trials in Rheumatoid arthritis in Japan (SC)
  • 30 Jun 2015 Ozoralizumab licensed to Taisho Pharmaceutical for development and commercialisation in Japan
  • 25 Jun 2012 Interim efficacy data from an open-label phase II trial in Rheumatoid arthritis released by Ablynx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top